New hope for advanced stomach cancer: triple therapy shows promise
NCT ID NCT05632939
First seen Nov 01, 2025 · Last updated May 09, 2026 · Updated 27 times
Summary
This study tests a new drug, ASKB589, combined with chemotherapy (CAPOX) and an immunotherapy (PD-1 inhibitor) in 62 people with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see if the combination is safe and helps control the cancer. Participants must have a specific marker (CLDN18.2) on their tumor cells.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100089, China
Conditions
Explore the condition pages connected to this study.